Compare ADNT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | NVAX |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | ADNT | NVAX |
|---|---|---|
| Price | $19.53 | $6.75 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 8 |
| Target Price | ★ $21.90 | $9.75 |
| AVG Volume (30 Days) | 1.2M | ★ 3.3M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $14,535,000,000.00 | $1,064,651,000.00 |
| Revenue This Year | $1.36 | $58.91 |
| Revenue Next Year | $2.11 | N/A |
| P/E Ratio | ★ N/A | $3.22 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $10.04 | $5.01 |
| 52 Week High | $26.16 | $11.55 |
| Indicator | ADNT | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 43.34 |
| Support Level | $18.67 | $6.36 |
| Resistance Level | $19.96 | $6.76 |
| Average True Range (ATR) | 0.67 | 0.22 |
| MACD | 0.21 | 0.05 |
| Stochastic Oscillator | 64.84 | 47.39 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.